Frontlight ResearchEarly access
CompletedPhase 1
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
Key facts
- Who runs it
- Longbio Pharma
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 60 people enrolled
- Started
- 13 Jul 2022
- Ended
- 4 Mar 2024
- Type of study
- Interventional, 10 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LP-003 Dose 1 (Single)
- LP-003 Dose 2 (Single)
- LP-003 Dose 3 (Single)
- LP-003 Dose 4 (Single)
- LP-003 Dose 5 (Single)
- Placebo (Single)
- LP-003 Dose 6 (Multiple)
- LP-003 Dose 7 (Multiple)
- LP-003 Dose 8 (Multiple)
- Placebo (Multiple)
- Record updated
- 12 December 2025
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Healthy males or females aged 18 through 50 years
- Male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a BMI between 19.0 and 28.0 kg/m² (inclusive)
- Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs
- The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent
- The subjects were able to communicate well with the researchers and complete the study according to the protocol
Who cannot take part
- Patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period
- Any history of infection within 14 days prior to administration
- A person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration
- Patients who have received any biological agent (including antibodies or derivatives such as omalizumab) within 16 weeks prior to administration (or 5 half-lives, selecting the longer time period)
- Participants who had participated in other clinical trials within 3 months prior to screening
- People who are allergic to the experimental drug and any of its excipients, have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food
- Patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results
- Hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, treponema pallidum antibodies A positive person
- The investigator deems any condition unsuitable for study participation
- Pregnant and lactating women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).
The 10 groups in the trial
- Cohort 1: LP-003 Dose 1 (Single)Treatment being tested
Treatment: LP-003 Dose 1 (Single)
- Cohort 2: LP-003 Dose 2 (Single)Treatment being tested
Treatment: LP-003 Dose 2 (Single)
- Cohort 3: LP-003 Dose 3 (Single)Treatment being tested
Treatment: LP-003 Dose 3 (Single)
- Cohort 4: LP-003 Dose 4 (Single)Treatment being tested
Treatment: LP-003 Dose 4 (Single)
- Cohort 5: LP-003 Dose 5 (Single)Treatment being tested
Treatment: LP-003 Dose 5 (Single)
- Cohort 6: Placebo (Single)Placebo, for comparison
Treatment: Placebo (Single)
- Cohort 7: LP-003 Dose 6 (Multiple)Treatment being tested
Treatment: LP-003 Dose 6 (Multiple)
- Cohort 8: LP-003 Dose 7 (Multiple)Treatment being tested
Treatment: LP-003 Dose 7 (Multiple)
- Cohort 9: LP-003 Dose 8 (Multiple)Treatment being tested
Treatment: LP-003 Dose 8 (Multiple)
- Cohort 10: Placebo (Multiple)Placebo, for comparison
Treatment: Placebo (Multiple)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers
- Record updated
- 12 December 2025